Flunisolide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Inhalation Asthma As metered dose aerosol using CFC propellant: 500 mcg twice daily, up to 2 mg/day in severe cases. Nasal Allergic rhinitis Per metered spray contains 25 mcg: Initial: 2 sprays into each nostril twice daily, may increase to 3 times/day if needed, then reduce for maintenance.
Dosage Details
Inhalation/Respiratory
Asthma
Adult: As a metered-dose aerosol using chlorofluorocarbon (CFC) propellant: 500 mcg bid up to 2 mg/day in severe asthma.
Child: >6-15 yr: As a metered-dose aerosol using chlorofluorocarbon (CFC) propellant: Not to exceed 500 mcg bid.

Nasal
Treatment and prophylaxis of allergic rhinitis
Adult: Per metered spray contains 25 mcg: Initially, 2 sprays into each nostril bid, may increase to tid if needed, then reduce for maintenance.
Child: 6-14 years: Per metered spray contains 25 mcg: 1 spray into each nostril up to tid. Max dose: 4 sprays (200 mcg) daily.
Contraindications
Hypersensitivity; presence of untreated acute infections; active or quiscent tuberculosis; ulcerative conditions.
Special Precautions
Congestive heart failure; recent myocardial infarction; hypertension; diabetes mellitus; epilepsy; glaucoma; hypothyroidism; osteoporosis; peptic ulceration; psychoses; renal or hepatic impairment; elderly; childn; pregnancy and lactation.
Adverse Reactions
Osteoporosis; muscle wasting; hyperglycaemia; impaired tissue repair; delayed wound healing; amenorrhoea, hyperhidrosis; ocular changes; mental and neurological disturbances; increased susceptiblity to infections.
Inhalation/Respiratory/Nasal: C
Drug Interactions
GI bleeding and ulceration with NSAIDs. Decreased serum concentrations of salicylates. Decreased effect with barbiturates, carbamezepine, pheytoin, primidone or rifampicin.
Potentially Fatal: Hypokalaemia with potassium-depleting drugs such as thiazide, furosemide or amphotericin B.
Action
Description: Flunisolide exerts glucocorticoid activity exhibiting potent anti-inflammatory and immunosuppressive effects, at least partly through inhibition of the release of various cytokines.
Pharmacokinetics:
Absorption: Absorbed following intranasal administration.
Metabolism: Extensive 1st pass metabolism (only 20% of dose systemically available); converted to 6β-hydroxyflunisolide (has little glucocorticoid activity).
Excretion: 4 hrs (elimination half-life).
Storage
Store at 15-25°C.
Disclaimer: This information is independently developed by MIMS based on Flunisolide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in